DC-BPi-03

CAS No. 2758411-46-8

DC-BPi-03( —— )

Catalog No. M36511 CAS No. 2758411-46-8

DC-BPi-03 is a potent BPTF-BRD inhibitor, exhibiting an IC50 of 698.3 nM and a Kd of 2.81 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 86 In Stock
5MG 79 In Stock
10MG 128 In Stock
25MG 258 In Stock
50MG 407 In Stock
100MG 641 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DC-BPi-03
  • Note
    Research use only, not for human use.
  • Brief Description
    DC-BPi-03 is a potent BPTF-BRD inhibitor, exhibiting an IC50 of 698.3 nM and a Kd of 2.81 μM.
  • Description
    DC-BPi-03 is a potent BPTF-BRD inhibitor with an IC50 of 698.3 nM and a Kd of 2.81 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2758411-46-8
  • Formula Weight
    302.35
  • Molecular Formula
    C14H14N4O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 33.33 mg/mL (110.24 mM; Ultrasonic (<80°C)
  • SMILES
    O=S(=O)(C=1N=C(C=C(N1)C2=CC=C3NC=CC3=C2)NC)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tian Lu, et al. Discovery of High-Affinity Inhibitors of the BPTF Bromodomain. J Med Chem. 2021 Aug 26;64(16):12075-12088.?
molnova catalog
related products
  • Pocenbrodib

    Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.

  • DW71177

    DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.

  • SRX3177

    SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.